CGPHF (Grand Pharmaceutical Group) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Grand Pharmaceutical Group 5-Year Yield-on-Cost %?

Grand Pharmaceutical Group CGPHF 86 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus rates CGPHF with a GF Score™ of 86/100. The stock has 6 warning signs investors should review. Among 513 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 88.89% on this metric.

Grand Pharmaceutical Group's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Grand Pharmaceutical Group's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Grand Pharmaceutical Group's highest Yield on Cost was 18.86. The lowest was 3.17. And the median was 7.84.


CGPHF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Grand Pharmaceutical Group  (OTCPK:CGPHF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Grand Pharmaceutical Group 5-Year Yield-on-Cost % Related Terms

CGPHF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Pharmaceutical Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's 5-Year Yield-on-Cost % falls into.


Grand Pharmaceutical Group 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Grand Pharmaceutical Group is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Grand Pharmaceutical Group (CGPHF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Grand Pharmaceutical Group and its competitors. Over the past decade, Grand Pharmaceutical Group's 5-Year Yield-on-Cost % has ranged from 3.17 to 18.86. According to the industry distribution chart, Grand Pharmaceutical Group ranks #57 out of 513 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Grand Pharmaceutical Group's 5-Year Yield-on-Cost % too high?
Grand Pharmaceutical Group's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 18.86. Based on the distribution chart, Grand Pharmaceutical Group ranks #57 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #57 out of 513 companies for 5-Year Yield-on-Cost %. This places Grand Pharmaceutical Group in the top 11% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Historically, Grand Pharmaceutical Group's own 5-Year Yield-on-Cost % has ranged from 3.17 to 18.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.